Enveric Biosciences (NASDAQ:ENVB) Releases Quarterly Earnings Results, Beats Expectations By $0.30 EPS

Enveric Biosciences (NASDAQ:ENVB) announced its quarterly earnings data on Monday. The company reported ($0.25) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.55) by $0.30, Yahoo Finance reports.

Enveric Biosciences Stock Performance

Shares of NASDAQ:ENVB traded down $0.00 on Tuesday, hitting $0.52. 59,666 shares of the company were exchanged, compared to its average volume of 2,395,429. The company’s 50 day moving average price is $0.59 and its two-hundred day moving average price is $0.83. The firm has a market capitalization of $4.14 million, a price-to-earnings ratio of -0.08 and a beta of 0.74. Enveric Biosciences has a one year low of $0.41 and a one year high of $2.92.

Enveric Biosciences Company Profile

Enveric Biosciences, Inc, a biotechnology company, engages in the development of small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders. Its lead product candidates are EB-002, an active metabolite of psilocybin, which is in preclinical development stage for the treatment of anxiety disorders; and EB-003 that is in preclinical development stage for the treatment mental health.